ArticleScientific reports2026
Ecto-5'-nucleotidase/CD73 reduces COX-2 expression in activated macrophages.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Extracellular ATP (eATP) is a significant contributor of inflammation through enhanced expression of cyclooxygenase 2 (COX-2). In this study, we explored whether overexpression of ectonucleotidases such as ecto-5'-nucleotidase (NT5E, or CD73), responsible for the hydrolysis of AMP to adenosine, can modulate COX-2 expression in macrophages. CD73 was subcloned in both bacterial and mammalian expression vector systems. In the first model, recombinant CD73 was exogenously added into the media of J774A.1 macrophage cells co-stimulated with LPS and AMP. In the second model, J774A.1 cells were transfected with CD73 cloned in pcDNA3.1 vector and checked for the expression of COX-2 following treatment with LPS and AMP. In both models, CD73 activity was assessed by the release of inorganic phosphate from AMP. We found that CD73, when added exogenously to the media, reduced COX-2 expression in LPS-activated J774A.1 cells stimulated with ATP or AMP, the substrate of CD73. Similar effect was seen in CD73-transfected J774A.1 cells treated with LPS and AMP, and this effect was abolished by AMP-CP, the inhibitor of CD73. The decrease in COX-2 expression involved NF-κB pathway but not through p42/44 MAPK. Our results show that overexpression of CD73 reduced COX-2 expression by increasing the formation of adenosine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.